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BRIEF COMMUNICATION
SYNERGISTIC ACTION OF PRAZIQUANTEL AND HOST SPECIFIC IMMUNE RESPONSE AGAINST
Schistosoma mansoni AT DIFFERENT PHASES OF INFECTION
Fabio RIBEIRO(1), Rômulo Teixeira de MELLO(2), Carlos Alberto Pereira TAVARES(3), John Robert KUSEL(4) & Paulo Marcos Zech COELHO(1,5)
SUMMARY
The interaction between specific immune response to Schistosoma mansoni and praziquantel (PZQ) was studied in mice. In mice
harboring concomitant immunity, 6-day-old parasites treated with PZQ were more effectively removed than 24h treated parasites
despite both had a significant worm burden reduction when compared with respective treated controls. These results show that PZQ
can be effective at the skin and lung stages of parasite’s development mainly acting with a established specific immune response, and
particularly at the lung phase.
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The precise mechanisms by which praziquantel (PZQ) acts on
Schistosoma mansoni are not completely understood. Some of the PZQ
effects listed in the literature are: Ca2+ influx through the tegument leading
to an immediate muscular contraction6, it reveals hidden antigens in the
schistosome surface which are targets to the host immune response5, it
acts as a spacer between lipid molecules10, it interferes with membrane
internalization processes in different stages of the parasite, and also
depletes glutathione from the parasite8,9. BRINDLEY & SHER (1987)1
studying the synergistic action of PZQ and host immune response
compared the efficacy of PZQ between B cell depleted and
immunologically intact mice. It was observed that in B cell-deficient
mice the schistosomicide effect of PZQ is strongly reduced or completely
abolished. Besides, the drug efficacy was completely restored by passive
transfer of immune serum obtained from S. mansoni infected donor mice
at the acute phase. FARAH et al. (2000)3 examined immunological
mechanisms associated with residual protection after chemotherapy and
concluded that the pattern of primary cercarial exposure determines
whether a secondary infection post PZQ treatment elicits a T helper 1 or
a T helper 2-associated immune response. Concomitant immunity is a
concept which was first utilized by SMITHERS & TERRY (1969)11 in
order to describe the capacity of adult S. mansoni worms surviving in its
immunologically intact host. When this host is submitted to a challenge
infection, a partial protection against the juvenile parasite is established,
thus reducing significantly the worm burden from reinfection.
In the present study the synergistic action of praziquantel and host
specific immune response against a S. mansoni challenge infection was
evaluated in mice bearing a concomitant immunity. S. mansoni cercariae
(LE strain from Belo Horizonte, Brazil) were used for infection of female
Swiss mice. Perfusion of mice for worm burden counts was undertaken
as described by PELLEGRINO & SIQUEIRA (1956)7. Mice were
infected with 40 cercariae, subcutaneous route. One hundred days after
primary infection, the animals were reinfected with ± 40 cercariae,
transcutaneous route, and distributed into 6 different groups, as follows:
D1- Infected, reinfected and treated with PZQ (500 mg kg-1) 24 h
after reinfection.
D2 - Infected, reinfected and treated with PZQ (500 mg kg-1) 6 days
after reinfection.
D3 - Infected, reinfected and untreated with PZQ.
D4 - Infected and treated with PZQ (500 mg kg-1) 24 h after infection.
D5 - Infected and treated with PZQ (500 mg kg-1) 6 days after
infection.
D6 - Infected and untreated.
Groups D4, D5 and D6 received just one infection, at the same
moment when groups D1 and D2 were reinfected. Twenty days after
reinfection, all the animals were individually perfused for worm burden
evaluation. Adult worms proceeding from primary infection, as well as
immature worms from reinfection were counted. Mice were treated with
PZQ, single dose by oral route. The worm burden reduction was
calculated using the following formula: [(C-T)\C] x 100 where C
represents the mean worm recovery from control group, and T represents
the mean worm recovery from experimental group.
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As can be seen in Table 1, a more noticeable decrease of worm burden
(p < 0.0002) was observed in the infected mice group, which was
reinfected and treated with PZQ, 6 days after reinfection (lung phase,
group D2). This group presented a mean of 3.0 ± 1.7 worms/mouse,
whereas its respective control group (D3) showed 12.9 ± 3.6 worms
(76% worm burden reduction). Our results also demonstrated that mice
bearing concomitant immunity established by infection and reinfection
(D1) presented a significant reduction of worm burden (p < 0.01), when
compared with the group that received a primary infection only (D4).
The concomitant immunity was able to potentiate significantly the PZQ
activity (D2 x D5 / p < 0.04), when treatment of mice was administered
at the lung phase, after reinfection. Association between concomitant
immunity and PZQ effect against S. mansoni, at lung phase after
reinfection, demonstrated a clear synergism between drug and host’s
immune system. Worm burden reduction in mice treated one day (skin
phase) after reinfection was not statistically significant when compared
with their respective controls. The greater activity of PZQ detected in
the group treated at the lung phase is corroborated by the results obtained
by WILSON, COULSON & DIXON (1986)12, who found pronounced
evidence that lung would be the main site of the host’s immune attack
against schistosomules, resulting in a marked elimination of parasites. It
seems that the mode of action of PZQ depends on the experimental murine
model, on the site of the parasite’s location during treatment, and on the
type of immunity established against S. mansoni. Our results
demonstrated an increase in the schistosomicide efficacy of PZQ in
association with the immune response, since treatment administered on
the mice group bearing concomitant immunity against S. mansoni, with
a sub-curative dose of 500 mg kg-1 PZQ, was able to eliminate
significantly more schistosomules at the lung stage than its respective
control group. Concomitant immunity was clearly demonstrated by 22%
worm burden reduction in infected/reinfected not treated group (D3)
compared with infected not treated (D6) control group. In concomitant
immunity a part of reduction in worm burden from reinfection would be
due to recirculation of juvenile worms - that at the moment of perfusion
would be in other sites of the organism (mainly in the lungs) and,
therefore, would not be taken into account for statistical estimation -
than to a true protective immunity. Juvenile worm recirculation would
occur through porto-cava shunts resulting from portal hypertension
typical of the disease2,13. To achieve 50% worm burden reduction in mice
treated at 28 days after reinfection, it was necessary to use 1000 mg kg-1
PZQ, a higher PZQ concentration than that required for an effective
therapeutic dose (data not shown). ELISA demonstrated that total IgG
antibodies level against SWAP (Fig. 1) were higher in groups infected,
reinfected and treated with 500 mg kg-1 PZQ, either at skin (D1) or lung
(D2) phases, and in the group of mice infected, reinfected and not treated
(D3). The total IgG antibodies level against SEA were similar to anti-
SWAP IgG antibodies level (unpublished data). IgG antibodies anti-
schistosomule antigens (Fig. 2) were also detected, however in lower
Table 1
Evaluation of worm burden in Swiss mice previously infected with S. mansoni, reinfected with 40 cercariae, and treated with 500 mg kg-1 PZQ at skin and lung
phases after reinfection
Groups Mean of immature worms ± SD (n)? Worm burden   Reduction (%) Significance  level
Inf./untreated (D6) 16.6 ± 2.8 (15) - D1 x D2 < 0.007
Inf./Reinf./untreated (D3) 12.9 ± 3.6 (11) 22.6 D6 x D3 < 0.01
Inf./PZQ 24 h (D4) 7.4 ± 2.4 (15) 42.6 D1 x D4 = NS*
Inf./Reinf./PZQ 24 h (D1) 6.7 ± 4.0 (15) 48.1 D1 x D3 < 0.05
Inf./PZQ 6 d (D5) 5.4 ± 3.4 (15) 58.1 D2 x D5 < 0.04
Inf./Reinf./PZQ 6 d (D2) 3.0 ± 1.7 (15) 76.7 D2 x D3 < 0.0002
*NS = Not significant; ?(n) = Number of mice/group.
Fig. 1 - Total IgG antibodies against soluble worm antigens preparation (SWAP) of S. mansoni.
D1) infected/reinfected/treated mice with PZQ 500 mg kg-1 one day after reinfection. D2)
infected/reinfected/treated mice with PZQ 500 mg kg-1 six days after reinfection. D3) infected/
reinfected/ not-treated mice. D4) infected/treated mice with PZQ 500 mg kg-1 one day after
infection. D5) infected/treated mice with PZQ 500 mg kg-1 six days after reinfection. CP e
CN means positive (mice at the chronic phase of infection) and negative control sera,
respectively. Bars represent mean + SD.
Fig. 2 - Total IgG antibodies against S. mansoni schistosomula antigens. D1) infected/
reinfected/treated mice with PZQ 500 mg kg-1 one day after reinfection. D2) infected/reinfected/
treated mice with PZQ 500 mg kg-1 six days after reinfection. D3) infected/reinfected/not-
treated mice. D4) infected/treated mice with PZQ 500 mg kg-1 one day after infection. D5)
infected/treated mice with PZQ 500 mg kg-1 six days after reinfection. CP e CN means
positive (mice at the chronic phase of infection) and negative control sera, respectively. Bars
represent mean + SD.
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level than IgG anti-SWAP antigens. Those groups that received just one
infection and were treated at skin and lung phases (D4 and D5) with the
same PZQ concentration failed to show a significant antibody response
against the tested antigens. The differences in drug activity might be
associated with several aspects related to evolutionary phase of the
parasite in its host. A better understanding of the S. mansoni physiology
during its development and the interactions between host specific immune
response and parasite will be necessary to explain diminished drug
efficacy on 28 day old immature S. mansoni.
RESUMO
Ação sinergística do praziquantel e resposta imune específica do
hospedeiro ao Schistosoma mansoni em diferentes fases da infecção
A interação entre a resposta imune específica ao Schistosoma mansoni
e praziquantel (PZQ) foi avaliada em modelo murino. Em camundongos
portadores de imunidade concomitante, parasitos com 6 dias de idade e
tratados com PZQ, foram eliminados mais eficazmente do que parasitos
de apenas 24 h, apesar de ambos mostrarem uma redução significativa
da carga parasitária quando comparados com os respectivos controles
tratados. Estes resultados mostram que o PZQ pode ser eficaz nos estágios
de pele e pulmão durante o desenvolvimento do parasita, agindo
principalmente com uma resposta imune específica estabelecida e,
particularmente, na fase pulmonar.
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